Macrocyclic purines for the treatment of viral infections

• US 10,280,180 B2
• Filed: 07/12/2013
• Issued: 05/07/2019
• Est. Priority Date: 07/13/2012
• Status: Active Grant

• Current Assignee: Janssen Sciences Ireland Unlimited Company (Johnson & Johnson)
• Original Assignee: Janssen Sciences Ireland UC (Johnson & Johnson)
• Inventors: Bonfanti, Jean-Francois, Fortin, Jerome Michel Claude, Muller, Philippe, Doublet, Frederic Marc Maurice, Raboisson, Pierre Jean-Marie Bernard, Arnoult, Eric Pierre Alexandre
• Primary Examiner(s): Jarrell, Noble E
• Application Number:
  US14/408,681
• Publication Number:
  US 20150299221A1
• Time in Patent Office: 2,125 Days
• Field of Search: None
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 487/16 Peri-condensed systems
• CPC Class Codes: C07D 487/22 in which the condensed system contains four or more hetero rings
• CPC Class Codes: C07D 498/16 Peri-condensed systems
• CPC Class Codes: C07D 498/22 in which the condensed system contains four or more hetero rings

Abstract

This invention relates macrocyclic purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Claims

1. A compound having formula (I)

3. A pharmaceutical composition comprising a compound having formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 and one or more pharmaceutically acceptable excipients, diluents or carriers.

4. A method of activating TLR7 in a subject comprising administering to the subject a therapeutically effective amount of a compound as claimed in claim 1.

7. A method of inducing interferon in a subject comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

2. A compound selected from the group consisting of:

5. A pharmaceutical composition comprising a compound according to claim 2 and at least one pharmaceutically acceptable excipient, diluent or carrier.

6. A method of activating TLR7 in a subject comprising administering to the subject a therapeutically effective amount of a compound according to claim 2.

8. A method of inducing interferon in a subject comprising administering to the subject a therapeutically effective amount of a compound of claim 2.